"Surging" Boehringer licenses GLP-1 follow-on compound from Zealand
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is "surging ahead" in the diabetes space, prompting Zealand Pharma to partner with it for its dual-acting glucagon and GLP-1 receptor agonist programme for the treatment of type 2 diabetes and obesity, Zealand's CEO David Solomon told Scrip.